Top

Published in:

01-03-2018 | Review Article

Metastatic Renal Cell Cancer—Systemic Therapy

Authors: Amit Joshi, Arvind Sahu, Vanita Noronha, Vijay Patil, Kumar Prabhash

Published in: Indian Journal of Surgical Oncology | Issue 1/2018

Abstract

Management of metastatic renal cell carcinoma (mRCC) has evolved considerably in the past 10 years due to better understanding of tumor biology. This development has changed mRCC to a chronic progressive disease with several lines of treatment options. The introduction of several new targeted therapies including immunotherapy has improved median overall survival of approximately 1 year to >2 years in mRCC.

Escudier B, Eisen T, Porta C, Patard JJ, Khoo V, Algaba F et al (2012) Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 23(suppl 7):vii65–vii71CrossRefPubMed

Karumanchi SA, Merchan J, Sukhatme VP (2002) Renal cancer: molecular mechanisms and newer therapeutic options. Curr Opin Nephrol Hypertens 11(1):37–42CrossRefPubMed

Ljungberg B, Campbell SC, Choi HY, Cho HY, Jacqmin D, Lee JE et al (2011) The epidemiology of renal cell carcinoma. Eur Urol 60(4):615–621. https://doi.org/10.1016/j.eururo.2011.06.049 CrossRefPubMed

Lekanidi K, Vlachou PA, Morgan B, Vasanthan S (2007) Spontaneous regression of metastatic renal cell carcinoma: case report. J Med Case Rep 1(1):89. https://doi.org/10.1186/1752-1947-1-89 CrossRefPubMedPubMedCentral

Lokich J (1997) Spontaneous regression of metastatic renal cancer. Case report and literature review. Am J Clin Oncol 20(4):416–418. https://doi.org/10.1097/00000421-199708000-00020 CrossRefPubMed

Attig S, Hennenlotter J, Pawelec G, Klein G, Koch SD, Pircher H, Feyerabend S, Wernet D, Stenzl A, Rammensee HG, Gouttefangeas C (2009) Simultaneous infiltration of polyfunctional effector and suppressor T cells into renal cell carcinomas. Cancer Res 69(21):8412–8419. https://doi.org/10.1158/0008-5472.CAN-09-0852 CrossRefPubMed

Schendel DJ, Gansbacher B, Oberneder R, Kriegmair M, Hofstetter A, Riethmüller G et al (1993) Tumor-specific lysis of human renal cell carcinomas by tumor-infiltrating lymphocytes. I. HLA-A2-restricted recognition of autologous and allogeneic tumor lines. J Immunol Baltim Md 1950 151(8):4209–4220

Fisher RI, Rosenberg SA, Fyfe G (2000) Long-term survival update for high-dose recombinant interleukin-2 in patients with renal cell carcinoma. Cancer J Sci Am 6(Suppl 1):S55–S57PubMed

Rosenberg SA, Yang JC, Topalian SL, Schwartzentruber DJ, Weber JS, Parkinson DR, Seipp CA, Einhorn JH, White DE (1994) Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin 2. JAMA 271(12):907–913. https://doi.org/10.1001/jama.1994.03510360033032 CrossRefPubMed

10.

Sd F (2000) Interferon in metastatic renal cell carcinoma. Semin Oncol. 27(2):187–193

11.

Rj A (2000) Chemotherapy for renal cell carcinoma. Semin Oncol 27(2):177–186

12.

Yagoda A, Petrylak D, Thompson S (1993) Cytotoxic chemotherapy for advanced renal cell carcinoma. Urol Clin North Am 20(2):303–321PubMed

13.

Latif F, Tory K, Gnarra J, Yao M, Duh FM, Orcutt ML et al (1993) Identification of the von Hippel-Lindau disease tumor suppressor gene. Science 260(5112):1317–1320. https://doi.org/10.1126/science.8493574 CrossRefPubMed

14.

Maher ER, Neumann HP, von Richard S (2011) Hippel–Lindau disease: a clinical and scientific review. Eur J Hum Genet 19(6):617–623. https://doi.org/10.1038/ejhg.2010.175 CrossRefPubMedPubMedCentral

15.

Leung SK, Ohh M (2002) Playing tag with HIF: the VHL story. J Biomed Biotechnol 2(3):131–135. https://doi.org/10.1155/S1110724302205057 CrossRefPubMedPubMedCentral

16.

Kim WY, Kaelin WG (2004) Role of VHL gene mutation in human cancer. J Clin Oncol Off J Am Soc Clin Oncol 22(24):4991–5004. https://doi.org/10.1200/JCO.2004.05.061 CrossRef

17.

Pugh CW, Ratcliffe PJ (2003) Regulation of angiogenesis by hypoxia: role of the HIF system. Nat Med 9(6):677–684. https://doi.org/10.1038/nm0603-677 CrossRefPubMed

18.

Kaelin WG (2002) Molecular basis of the VHL hereditary cancer syndrome. Nat Rev Cancer 2(9):673–682. https://doi.org/10.1038/nrc885 CrossRefPubMed

19.

Sufan RI, Jewett MAS, Ohh M (2004) The role of von Hippel-Lindau tumor suppressor protein and hypoxia in renal clear cell carcinoma. Am J Physiol Renal Physiol 287(1):F1–F6. https://doi.org/10.1152/ajprenal.00424.2003 CrossRefPubMed

20.

Barry RE, Krek W (2004) The von Hippel-Lindau tumour suppressor: a multi-faceted inhibitor of tumourigenesis. Trends Mol Med 10(9):466–472. https://doi.org/10.1016/j.molmed.2004.07.008 CrossRefPubMed

21.

Maxwell PH, Pugh CW, Ratcliffe PJ (2001) Activation of the HIF pathway in cancer. Curr Opin Genet Dev 11(3):293–299CrossRefPubMed

22.

de Paulsen N, Brychzy A, Fournier MC, Klausner RD, Gnarra JR, Pause A et al (2001) Role of transforming growth factor-alpha in von Hippel--Lindau (VHL)(-/-) clear cell renal carcinoma cell proliferation: a possible mechanism coupling VHL tumor suppressor inactivation and tumorigenesis. Proc Natl Acad Sci U S A 98(4):1387–1392PubMedPubMedCentral

23.

Lolkema MP, Gervais ML, Snijckers CM, Hill RP, Giles RH, Voest EE, Ohh M (2005) Tumor suppression by the von Hippel-Lindau protein requires phosphorylation of the acidic domain. J Biol Chem 280(23):22205–22211. https://doi.org/10.1074/jbc.M503220200 CrossRefPubMed

24.

Kurban G, Hudon V, Duplan E, Ohh M, Pause A (2006) Characterization of a von Hippel Lindau pathway involved in extracellular matrix remodeling, cell invasion, and angiogenesis. Cancer Res 66(3):1313–1319. https://doi.org/10.1158/0008-5472.CAN-05-2560 CrossRefPubMed

25.

Simons M, Walz G (2006) Polycystic kidney disease: cell division without a c(l)ue? Kidney Int 70(5):854–864. https://doi.org/10.1038/sj.ki.5001534 CrossRefPubMed

26.

Thoma CR, Frew IJ, Hoerner CR, Montani M, Moch H, Krek W (2007) pVHL and GSK3beta are components of a primary cilium-maintenance signalling network. Nat Cell Biol 9(5):588–595. https://doi.org/10.1038/ncb1579 CrossRefPubMed

27.

Frew IJ, Thoma CR, Georgiev S, Minola A, Hitz M, Montani M, Moch H, Krek W (2008) pVHL and PTEN tumour suppressor proteins cooperatively suppress kidney cyst formation. EMBO J 27(12):1747–1757. https://doi.org/10.1038/emboj.2008.96 CrossRefPubMedPubMedCentral

28.

Hergovich A, Lisztwan J, Barry R, Ballschmieter P, Krek W (2003) Regulation of microtubule stability by the von Hippel-Lindau tumour suppressor protein pVHL. Nat Cell Biol 5(1):64–70. https://doi.org/10.1038/ncb899 CrossRefPubMed

29.

Hergovich A, Lisztwan J, Thoma CR, Wirbelauer C, Barry RE, Krek W (2006) Priming-dependent phosphorylation and regulation of the tumor suppressor pVHL by glycogen synthase kinase 3. Mol Cell Biol 26(15):5784–5796. https://doi.org/10.1128/MCB.00232-06 CrossRefPubMedPubMedCentral

30.

Thoma CR, Toso A, Gutbrodt KL, Reggi SP, Frew IJ, Schraml P, Hergovich A, Moch H, Meraldi P, Krek W (2009) VHL loss causes spindle misorientation and chromosome instability. Nat Cell Biol 11(8):994–1001. https://doi.org/10.1038/ncb1912 CrossRefPubMed

31.

Pause A, Lee S, Lonergan KM, Klausner RD (1998) The von Hippel-Lindau tumor suppressor gene is required for cell cycle exit upon serum withdrawal. Proc Natl Acad Sci U S A 95(3):993–998. https://doi.org/10.1073/pnas.95.3.993 CrossRefPubMedPubMedCentral

32.

Kim J, Jonasch E, Alexander A, Short JD, Cai S, Wen S et al (2009) Cytoplasmic sequestration of p27 via AKT phosphorylation in renal cell carcinoma. Clin Cancer Res Off J Am Assoc Cancer Res 15(1):81–90CrossRef

33.

Roe J-S, Kim H-R, Hwang I-Y, Cho E-J, Youn H-D (2011) von Hippel-Lindau protein promotes Skp2 destabilization on DNA damage. Oncogene 30(28):3127–3138. https://doi.org/10.1038/onc.2011.40 CrossRefPubMed

34.

Roe J-S, Kim H, Lee S-M, Kim S-T, Cho E-J, Youn H-D (2006) p53 stabilization and transactivation by a von Hippel-Lindau protein. Mol Cell 22(3):395–405. https://doi.org/10.1016/j.molcel.2006.04.006 CrossRefPubMed

35.

Lai Y, Song M, Hakala K, Weintraub ST, Shiio Y (2011) Proteomic dissection of the von Hippel-Lindau (VHL) interactome. J Proteome Res 10(11):5175–5182. https://doi.org/10.1021/pr200642c CrossRefPubMedPubMedCentral

36.

Li M, Fang X, Baker DJ, Guo L, Gao X, Wei Z, Han S, van Deursen JM, Zhang P (2010) The ATM-p53 pathway suppresses aneuploidy-induced tumorigenesis. Proc Natl Acad Sci U S A 107(32):14188–14193. https://doi.org/10.1073/pnas.1005960107 CrossRefPubMedPubMedCentral

37.

Escudier B, Eisen T, Stadler WM, Szczylik C, Oudard S, Siebels M, Negrier S, Chevreau C, Solska E, Desai AA, Rolland F, Demkow T, Hutson TE, Gore M, Freeman S, Schwartz B, Shan M, Simantov R, Bukowski RM, TARGET Study Group (2007) Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 356(2):125–134. https://doi.org/10.1056/NEJMoa060655 CrossRefPubMed

38.

Eisen T, Oudard S, Szczylik C, Gravis G, Heinzer H, Middleton R, Cihon F, Anderson S, Shah S, Bukowski R, Escudier B, for the TARGET Study Group (2008) Sorafenib for older patients with renal cell carcinoma: subset analysis from a randomized trial. J Natl Cancer Inst 100(20):1454–1463. https://doi.org/10.1093/jnci/djn319 CrossRefPubMedPubMedCentral

39.

Escudier B, Szczylik C, Hutson TE, Demkow T, Staehler M, Rolland F, Negrier S, Laferriere N, Scheuring UJ, Cella D, Shah S, Bukowski RM (2009) Randomized phase II trial of first-line treatment with sorafenib versus interferon Alfa-2a in patients with metastatic renal cell carcinoma. J Clin Oncol Off J Am Soc Clin Oncol 27(8):1280–1289. https://doi.org/10.1200/JCO.2008.19.3342 CrossRef

40.

Amato R, Zhai J, Willis J, Saxena S, DeFoe MA (2012) Phase II trial of intrapatient dose-escalated sorafenib in patients with metastatic renal cell carcinoma. Clin Genitourin Cancer 10(3):153–158CrossRefPubMed

41.

Hutson TE (2011) Targeted therapies for the treatment of metastatic renal cell carcinoma: clinical evidence. Oncologist 16(Suppl 2):14–22. https://doi.org/10.1634/theoncologist.2011-S2-14 CrossRefPubMedPubMedCentral

42.

Logan JE, Rampersaud EN, Sonn GA, Chamie K, Belldegrun AS, Pantuck AJ, Slamon DJ, Kabbinavar FF (2012) Systemic therapy for metastatic renal cell carcinoma: a review and update. Rev Urol 14(3–4):65–78PubMedPubMedCentral

43.

Abrams TJ, Lee LB, Murray LJ, Pryer NK, Cherrington JM (2003) SU11248 inhibits KIT and platelet-derived growth factor receptor beta in preclinical models of human small cell lung cancer. Mol Cancer Ther 2(5):471–478CrossRefPubMed

44.

Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Rixe O, Oudard S, Negrier S, Szczylik C, Kim ST, Chen I, Bycott PW, Baum CM, Figlin RA (2007) Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 356(2):115–124. https://doi.org/10.1056/NEJMoa065044 CrossRefPubMed

45.

Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Oudard S, Negrier S, Szczylik C, Pili R, Bjarnason GA, Garcia-del-Muro X, Sosman JA, Solska E, Wilding G, Thompson JA, Kim ST, Chen I, Huang X, Figlin RA (2009) Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol Off J Am Soc Clin Oncol 27(22):3584–3590. https://doi.org/10.1200/JCO.2008.20.1293 CrossRef

46.

Motzer RJ, Hutson TE, Olsen MR, Hudes GR, Burke JM, Edenfield WJ, Wilding G, Agarwal N, Thompson JA, Cella D, Bello A, Korytowsky B, Yuan J, Valota O, Martell B, Hariharan S, Figlin RA (2012) Randomized phase II trial of sunitinib on an intermittent versus continuous dosing schedule as first-line therapy for advanced renal cell carcinoma. J Clin Oncol Off J Am Soc Clin Oncol 30(12):1371–1377. https://doi.org/10.1200/JCO.2011.36.4133 CrossRef

47.

Sternberg CN, Davis ID, Mardiak J, Szczylik C, Lee E, Wagstaff J, Barrios CH, Salman P, Gladkov OA, Kavina A, Zarbá JJ, Chen M, McCann L, Pandite L, Roychowdhury DF, Hawkins RE (2010) Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol Off J Am Soc Clin Oncol 28(6):1061–1068. https://doi.org/10.1200/JCO.2009.23.9764 CrossRef

48.

Motzer RJ, Hutson TE, Cella D, Reeves J, Hawkins R, Guo J, Nathan P, Staehler M, de Souza P, Merchan JR, Boleti E, Fife K, Jin J, Jones R, Uemura H, de Giorgi U, Harmenberg U, Wang J, Sternberg CN, Deen K, McCann L, Hackshaw MD, Crescenzo R, Pandite LN, Choueiri TK (2013) Pazopanib versus sunitinib in metastatic renal-cell carcinoma. N Engl J Med 369(8):722–731. https://doi.org/10.1056/NEJMoa1303989 CrossRefPubMed

49.

Escudier B, Porta C, Bono P, Powles T, Eisen T, Sternberg CN, Gschwend JE, de Giorgi U, Parikh O, Hawkins R, Sevin E, Négrier S, Khan S, Diaz J, Redhu S, Mehmud F, Cella D (2014) Randomized, controlled, double-blind, cross-over trial assessing treatment preference for pazopanib versus sunitinib in patients with metastatic renal cell carcinoma: PISCES Study. J Clin Oncol Off J Am Soc Clin Oncol 32(14):1412–1418. https://doi.org/10.1200/JCO.2013.50.8267 CrossRef

50.

Choueiri TK, Escudier B, Powles T, Mainwaring PN, Rini BI, Donskov F, Hammers H, Hutson TE, Lee JL, Peltola K, Roth BJ, Bjarnason GA, Géczi L, Keam B, Maroto P, Heng DY, Schmidinger M, Kantoff PW, Borgman-Hagey A, Hessel C, Scheffold C, Schwab GM, Tannir NM, Motzer RJ, METEOR Investigators (2015) Cabozantinib versus everolimus in advanced renal-cell carcinoma. N Engl J Med 373(19):1814–1823. https://doi.org/10.1056/NEJMoa1510016 CrossRefPubMedPubMedCentral

51.

Rini BI, Melichar B, Ueda T, Grünwald V, Fishman MN, Arranz JA, Bair AH, Pithavala YK, Andrews GI, Pavlov D, Kim S, Jonasch E (2013) Axitinib with or without dose titration for first-line metastatic renal-cell carcinoma: a randomised double-blind phase 2 trial. Lancet Oncol 14(12):1233–1242. https://doi.org/10.1016/S1470-2045(13)70464-9 CrossRefPubMedPubMedCentral

52.

Motzer RJ, Escudier B, Tomczak P, Hutson TE, Michaelson MD, Negrier S, Oudard S, Gore ME, Tarazi J, Hariharan S, Chen C, Rosbrook B, Kim S, Rini BI (2013) Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial. Lancet Oncol 14(6):552–562. https://doi.org/10.1016/S1470-2045(13)70093-7 CrossRefPubMed

53.

Hutson TE, Lesovoy V, Al-Shukri S, Stus VP, Lipatov ON, Bair AH, Rosbrook B, Chen C, Kim S, Vogelzang NJ (2013) Axitinib versus sorafenib as first-line therapy in patients with metastatic renal-cell carcinoma: a randomised open-label phase 3 trial. Lancet Oncol 14(13):1287–1294. https://doi.org/10.1016/S1470-2045(13)70465-0 CrossRefPubMed

54.

Hudes G, Carducci M, Tomczak P, Dutcher J, Figlin R, Kapoor A, Staroslawska E, Sosman J, McDermott D, Bodrogi I, Kovacevic Z, Lesovoy V, Schmidt-Wolf IG, Barbarash O, Gokmen E, O'Toole T, Lustgarten S, Moore L, Motzer RJ, Global ARCC Trial (2007) Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 356(22):2271–2281. https://doi.org/10.1056/NEJMoa066838 CrossRefPubMed

55.

Flaherty KT, Manola JB, Pins M, McDermott DF, Atkins MB, Dutcher JJ et al (2015) BEST: a randomized phase II study of vascular endothelial growth factor, RAF kinase, and mammalian target of rapamycin combination targeted therapy with bevacizumab, sorafenib, and temsirolimus in advanced renal cell carcinoma—a trial of the ECOG-ACRIN Cancer Research Group (E2804). J Clin Oncol Off J Am Soc Clin Oncol 33(21):2384–2391CrossRef

56.

Hutson TE, Escudier B, Esteban E, Bjarnason GA, Lim HY, Pittman KB, Senico P, Niethammer A, Lu DR, Hariharan S, Motzer RJ (2014) Randomized phase III trial of temsirolimus versus sorafenib as second-line therapy after sunitinib in patients with metastatic renal cell carcinoma. J Clin Oncol Off J Am Soc Clin Oncol 32(8):760–767. https://doi.org/10.1200/JCO.2013.50.3961 CrossRef

57.

Motzer RJ, Barrios CH, Kim TM, Falcon S, Cosgriff T, Harker WG, Srimuninnimit V, Pittman K, Sabbatini R, Rha SY, Flaig TW, Page R, Bavbek S, Beck JT, Patel P, Cheung F, Yadav S, Schiff EM, Wang X, Niolat J, Sellami D, Anak O, Knox JJ (2014) Phase II randomized trial comparing sequential first-line everolimus and second-line sunitinib versus first-line sunitinib and second-line everolimus in patients with metastatic renal cell carcinoma. J Clin Oncol Off J Am Soc Clin Oncol 32(25):2765–2772. https://doi.org/10.1200/JCO.2013.54.6911 CrossRef

58.

Motzer RJ, Escudier B, McDermott DF, George S, Hammers HJ, Srinivas S, Tykodi SS, Sosman JA, Procopio G, Plimack ER, Castellano D, Choueiri TK, Gurney H, Donskov F, Bono P, Wagstaff J, Gauler TC, Ueda T, Tomita Y, Schutz FA, Kollmannsberger C, Larkin J, Ravaud A, Simon JS, Xu LA, Waxman IM, Sharma P, CheckMate 025 Investigators (2015) Nivolumab versus everolimus in advanced renal-cell carcinoma. N Engl J Med 373(19):1803–1813. https://doi.org/10.1056/NEJMoa1510665 CrossRefPubMedPubMedCentral

Title: Metastatic Renal Cell Cancer—Systemic Therapy
Authors: Amit Joshi
Arvind Sahu
Vanita Noronha
Vijay Patil
Kumar Prabhash
Publication date: 01-03-2018
Publisher: Springer India
Published in: Indian Journal of Surgical Oncology / Issue 1/2018
Print ISSN: 0975-7651
Electronic ISSN: 0976-6952
DOI: https://doi.org/10.1007/s13193-018-0721-2

At a glance: The STEP trials

Springer Medicine

Metastatic Renal Cell Cancer—Systemic Therapy

Abstract

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2018

Solitary Primary Intraosseous Angiosarcoma of the Mandible

Philosophy on Neck Dissection in Thyroid Cancer—Current Controversies and Consensus

Importance of Number of Foci of Capsular Invasion in Follicular Thyroid Carcinoma

The Second Victim: Ignored in the Indian Perspective

Low-Grade Central Osteosarcoma: Report of Two Unusual Morphologic Variants

Aggressive Angioimmunoblastic T Cell Lymphomas (AITL) with Soft Tissue Extranodal Mass Varied Histopathological Patterns with Peripheral Blood, Bone Marrow, and Splenic Involvement and Review of Literature